Centocor, Inc.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Centocor products have also saved lives in the treatment of heart attacks and have been used to reduce risk of cardiac events in interventional cardiology.
Centocor continues to pioneer new pathways in biomedical research and development. Drug discovery and development efforts focus on the following therapeutic areas: I.M.I.D. (Immune Mediated Inflammatory Diseases) hematology/oncology, infectious diseases, metabolic diseases, inflammatory bowel disorders, pulmonary disorders, central nervous system disorders, dermatology, rheumatology and cardiovascular disease. Centocor is looking for novel approaches that address the pathology of these diseases.
The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson, a worldwide manufacturer of healthcare products.
Products:
REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both rheumatoid arthritis (RA) and Crohn's disease (CD) in North America, the European Union (EU) and Japan. In the EU and in the U.S., REMICADE is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis.
Senior Officers: Julie McHugh, President
Last Updated: 07-13-05